CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech Showcase in San Francisco
TUCSON, AZ / ACCESSWIRE / December 7, 2021 /Aqualung Therapeutics Corp., an early stage immunotherapeutics company which has developed an anti-inflammatory therapeutic platform for life-threatening unchecked inflammation, will be presenting at the annual Biotech Showcase in San Francisco in conjunction with the JP Morgan Healthcare conference, January 11th at 10:30am pacific time, Hilton Hotel, Franciscan C Ballroom.
As one of the biggest annual healthcare investor conferences, this allows Aqualung to provide a comprehensive update on the development of ALT-100 mAb in the treatment of Acute Respiratory Distress Syndrome (ARDS), and other key milestones accomplished over the last 12-18 months.
"It will be great to meet with some potential investors in a face-to-face forum and share the tremendous progress we have made over the last 18 months" states Stan Miele, President of Aqualung Therapeutics Corp. "Aqualung now has ~3500 vials of GMP manufactured ALT-100mAb, is finishing IND enabling toxicology studies, intends to file an IND with the FDA by the end of March 2022, and will initiate a human P1A healthy human volunteer study by the middle of 2022. This meeting is a tremendous launching pad for us to shore up our existing committed institutional investors and meet with other potential investors who may have an interest in participating in our Series A capital raise."
With still no FDA-approved ARDS therapies, and a mortality rate reaching 40%, there is a significant clinical need for novel therapies to treat such a vexing condition. Aqualung has spent years validating the use of ALT-100 in multiple pre-clinical models and is now ready to transition to the next important milestone of human trials.
The development of ALT-100 mAb is based upon the identification by Aqualung Therapeutics scientists of extracellular NAMPT or eNAMPT, as a master regulator of tissue and systemic inflammation and as a novel therapeutic target in ARDS, along with other chronic indications such as Pulmonary Arterial Hypertension, Radiation Induced Lung Injury, and Prostate Cancer. "I am very much looking forward to sharing our latest extraordinarily exciting data that underscores the therapeutic capacity for targeting eNAMPT and providing a business update on how we are certainly meeting all of our key milestones" states Joe GN Garcia MD., CEO and Founder of Aqualung Therapeutics.
About Aqualung Therapeutics Corporation
Aqualung is an early-stage biotech immunotherapeutics company which has developed an anti-inflammatory therapeutic platform for patients life-threatening unchecked inflammation. Founded in 2016 and led by a physician-scientist, Aqualung's science-driven approaches led to the identification of nicotinamide phosphoribosyltransferase (NAMPT) as a major contributor to the severity of potentially fatal inflammatory diseases. Aqualung Therapeutics has developed eNamptor™, a Next Gen platform comprised of: i) the humanized ALT 100 mAb, an eNAMPT-neutralizing monoclonal antibody; ii) eNAMPT-Plex, a plasma-based biomarker panel comprised of cytokines and eNAMPT, which predicts ARDS mortality; and iii) NAMPT-Gene, a genotyping assay that identifies individuals genetic variants that predispose to ARDS risk and death. In addition to ARDS and ventilator-induced lung injury, the pipeline of ALT-100 mAb indications currently includes radiation-induced injuries, intrauterine infections during pregnancy (chorioamnionitis), prostate cancer, pulmonary hypertension, autoimmune disorders (IBD, SLE) and both pulmonary and hepatic fibrosis (NASH). Each of these potentially fatal inflammatory conditions exhibit significant unmet medical needs for therapeutics to reduce morbidity and mortality. For additional information about the company, please visitwww.aqualungtherapeutics.com.
SOURCE: Aqualung Therapeutics
View source version on accesswire.com:
© 2021 Accesswire. All Rights Reserved.